This trial is active, not recruiting.

Condition prostatic neoplasms
Treatment far infrared radiation
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date January 2006
End date February 2008
Trial size 4 participants
Trial identifier NCT00573820, GAAD-PC-CTP1


A study to determine the use of far infrared radiation for the treatment of prostate cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
far infrared radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.

Primary Outcomes

The primary end point is to determine the therapeutic effects of far infrared radiation on Prostate Cancer.
time frame: 2 years and 6 months

Secondary Outcomes

The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of cancer (Bladder and Testis).
time frame: 2 years and 6 months

Eligibility Criteria

Male participants of any age.

Inclusion Criteria: - Persons with Prostate, Bladder or Testicular Cancer. Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Prostate Cancer
Principal investigator Ken Nedd, M.D.
Description Our initial assessment indicates that electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to cure a number of diseases, including prostate cancer.
Trial information was received from ClinicalTrials.gov and was last updated in August 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..